trending Market Intelligence /marketintelligence/en/news-insights/trending/PsLFkOYraCI_1_2Kn3qMlw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sartorius 9-month net profit up 21.2% YOY

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sartorius 9-month net profit up 21.2% YOY

Sartorius AG, which develops pharmaceutical and laboratory equipment, said earnings for the first nine months of 2019 grew by 21.2% year over year.

The Göttingen, Germany-based company's nine-month net profit totaled €153.2 million, or €2.23 per share, up from €126.3 million, or €1.84 per share, a year earlier.

Consolidated sales revenue for the period reached €1.36 billion, a 17.5% year-over-year growth from €1.15 billion.

Sales from the company's bioprocess solutions segment amounted to €1.03 billion, up 21.6% on a reported basis from €843 million, in the same period of 2018, mainly driven by project business in Asia.

Sartorius' lab products and services division booked sales of €330.8 million, a 6.5% yearly increase on a reported basis from €310.7 million.

Nine-month EBITDA rose 22.7% to €361.1 million from €294.2 million in the year-ago period.

For the nine months ended Sept. 30, Sartorius unit Sartorius Stedim Biotech SA reported net profit €198.1 million, or €2.15 per share, up 23.3% from €160.7 million, or €1.74 per share, in the same period of 2018.

The Aubagne, France-based unit said sales revenue for the same period was €1.08 billion, up 20.2% on a reported basis from €896.1 million in the prior year.

Both Sartorius and Sartorius Stedim Biotech expect to reach the higher end of their sales forecast for 2019.

Sartorius previously said it expects sales revenue to increase by about 10% to 14% in constant currencies, while Sartorius Stedim Biotech projects sales revenue to increase by about 12% to 16%.

In other news, Sartorius agreed to acquire three businesses from Danaher Corp.'s life science portfolio for about $750 million in cash.